Business Wire

ANT-GROUP-DIGITAL

3.11.2022 10:19:44 CET | Business Wire | Press release

Share
Ant Group Digital Technologies Launches Storage Engine LETUS to Provide Trusted Storage Solutions for the Digital Economy

Ant Group Digital Technologies, a digital technology provider under Ant Group, today unveiled its blockchain storage engine “LETUS” (Log-structured Efficient Trusted Universal Storage) at the Apsara Conference 2022 in Hangzhou.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221103005680/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Yan Ying, Technical Director of AntChain, unveiled the LETUS at the Apsara Conference (Photo: Business Wire)

LETUS, which was developed and designed by the AntChain team, will increase the effectiveness and lower the storage costs for blockchain networks.

Blockchain is a distributed peer-to-peer network, with each node storing data such as blocks and states. The LETUS storage engine is deployed at each blockchain node to provide trusted storage support. At the same time, LETUS has the advantages in performance, large scale workloads handling capability, cost, and resource efficiency through Smart Thermo-control Tiering and Boundary Scan Based Batch Pruning.

“As more and more digital assets are stored on the blockchain, storage capacity and efficiency has increasing impact on the overall performance of blockchain platforms, including transaction speeds and operational costs,” said Yan Ying, Technical Director of AntChain. “Compared to current mainstream industry solutions, LETUS can improve storage throughput by 15 times, reduce latency by 90%, and save disk bandwidth and space usage by 95% and 60%, respectively."

LETUS has already been deployed and running in Topnod, a digital collectibles platform powered by AntChain. It has helped the platform greatly improve performance and reduce storage costs by about 75%.

“For the many industries undergoing digital transformations, mutual trust between companies and customers is increasingly important. At Ant, we have been investing in research and development for blockchain and other digital technologies that help to increase both trust and security,” said Geoff Jiang, President of Digital Technology Business Group at Ant Group. “We remain focused on the technological breakthroughs that create a trusted digital network to improve industrial collaboration and allow us to use our innovative products and services to better serve the real economy.”

During the conference, Ant Group Digital Technologies also released the:

  • 4.0 version of mPaaS, its one-stop mobile development solution;
  • 2.0 version of its Morse MPC (Multi-party Computation) platform;
  • 4.0 version of SOFAStack, its cloud-native PaaS platform;
  • 4.0 version of OceanBase Community Edition, its distributed database; and
  • other security products.

In the past two years, Ant Group Digital Technologies has also released a number of blockchain-related products and solutions, including:

  • AntChain Station, the all-in-one workstation;
  • Blockchain Transmission Network (BTN), a high-speed, long-distance blockchain communication technology;
  • Module-as-a-Service (MaaS) integrated computing module for simplified blockchain deployment;
  • FAIR, the data privacy collaboration platform; and
  • T1 security chip, its self-developed blockchain-powered security chip.

Many of these cutting-edge solutions have been successfully deployed by Chery Automobile, Zhejiang Huatie Emergency Equipment Science and Technology and other industry partners.

Ant Group Digital Technologies

Ant Group Digital Technologies continues to promote the development and application of digital technology, introducing leading products like AntChain, OceanBase, SOFAStack, and mPaaS based on its expertise in blockchain, privacy computing, security technology, and distributed database. Ant Group Digital Technologies is committed to working with partners across different industries to support the small and medium-sized financial institutions in their digital transformation, enable SMEs in the service industry to operate digitally and facilitate digital collaboration across industries.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005680/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 14:32:00 CEST | Press release

Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company'

SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 14:00:00 CEST | Press release

Integrated subsea production system and local capabilities enable accelerated deepwater development Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, um

HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 14:00:00 CEST | Press release

HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev

Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 14:00:00 CEST | Press release

ArcGIS Velocity Brings Real-Time Data Ingestion, Analysis, and Automated Alerting to ArcGIS Enterprise Deployments Esri announces that ArcGIS Velocity is now available for ArcGIS Enterprise, enabling real-time data analytics and automated actions in self-hosted environments. This capability’s new deployment unifies real-time workflows across ArcGIS Online and ArcGIS Enterprise. This update benefits organizations across industries: public safety, transportation, logistics, and more. Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT),

Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 12:00:00 CEST | Press release

$85M upfront financing, along with up to $255 million upon exercise of purchase warrants, is expected to fund ROBBIN1, Agenus' registrational Phase 3 trial of neoadjuvant botensilimab and balstilimab (BOT+BAL) in microsatellite-stable (MSS) colon cancer Transaction is structured to fund Agenus through key value-inflection points, including interim topline pathologic response data and interim and final event-free survival (EFS) analyses, with proceeds to fund Agenus operations through year-end 2031, assuming full warrant exercise ROBBIN target population in MSS colon cancer represents a >$7 billion addressable annual sales opportunity in the US for which no new therapies have been approved in over 20 years2,3 To focus resources on the neoadjuvant opportunity, Agenus is discontinuing financial support for the ongoing BATTMAN Phase 3 study in late-line metastatic MSS colorectal cancer Company to host conference call and webcast today at 8:30 a.m. ET Agenus Inc. (Nasdaq: AGEN), a leader in

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye